Microsatellite instability markers in detection of cancer
AssigneesLife Sciences Research Partners VZW, Vib Vzw
InventorDiether Lambrechts
Life of this patent
Estimating the term…
Abstract
The present application relates to the field of cancer, particularly to mismatch repair (MMR−) deficient tumors. New markers are presented herein that have a high sensitivity to detect whether a tumor is mismatch repair deficient or not. The markers are particularly mutations in microsatellite regions. Accordingly, methods are provided for diagnosing microsatellite instability of a tumor, comprising determining the presence of these markers. Further, kits are provided to detect the presence of these markers (or subsets thereof) in a sample.
Claims24
A kit for determining microsatellite instability in 4 to 107 microsatellite regions of a tumor or cancer sample, the kit comprising:
- labeled oligonucleotides to specifically genotype 4 to 107 microsatellite regions selected from those present in 5′ UTR or 3′ UTR regions from the genes listed in Table 1,
- wherein each of the labeled oligonucleotides comprises a sequence specifically hybridizing to one of the microsatellite regions;
- wherein the maximal amount of the labelled oligonucleotides the kit comprises is limited to the number necessary to specifically genotype the 4 to 107 microsatellite regions;
- and
- wherein the label of the labeled oligonucleotides is a non-nucleic acid label.
A kit for determining microsatellite instability in 4 to 138 microsatellite regions of a tumor or cancer sample, the kit comprising:
- labeled oligonucleotides to specifically genotype 4 to 138 microsatellite regions selected from those present in 5′ UTR or 3′ UTR regions from the genes listed in Table 1 and those present in the exons of the genes listed in Table 2,
- wherein the labeled oligonucleotides are 4 to 138 microsatellite region-specific primer and probe sets;
- wherein at least one primer or probe of each set comprises a sequence specifically hybridizing to one of the microsatellite regions;
- wherein at least one of the primer or probe of each set is labeled;
- wherein the label of the labeled oligonucleotides is a non-nucleic acid label.
A kit for determining microsatellite instability in 4 to 50 microsatellite regions of a tumor or cancer sample, the kit comprising labeled oligonucleotides to specifically genotype 4 to 50 of the microsatellite regions selected from the group consisting of those present in 5′ UTR or 3′ UTR regions from the genes listed in Table 1 and those present in the exons of the genes listed in Table 2;
- wherein the maximal amount of the labeled oligonucleotides the kit comprises for determining microsatellite instability is limited to the number necessary to specifically genotype the 4 to 50 microsatellite regions;
- and wherein the label of the labeled oligonucleotides is a non-nucleic acid label.
A kit for determining microsatellite instability in 4 to 50 microsatellite regions of a tumor or cancer sample, the kit comprising sets of oligonucleotides to specifically genotype 4 to 50 of the microsatellite regions selected from the group consisting of those present in 5′ UTR or 3′ UTR regions from the genes listed in Table 1 and those present in the exons of the genes listed in Table 2,
- wherein each set comprises a primer and probe(s) of which at least one is labeled;
- wherein the maximal amount of sets of oligonucleotides the kit comprises for determining microsatellite instability is limited to the number necessary to specifically genotype the 4 to 50 microsatellite regions;
- and wherein the label of the labeled primer or probe is a non-nucleic acid label.
A kit for determining microsatellite instability in at least 4 microsatellite regions of a tumor or cancer sample, the kit comprising:
- labeled oligonucleotides to genotype at least 4 of the microsatellite regions selected from the group consisting of those present in 5′ UTR or 3′ UTR regions from the genes listed in Table 1 and those present in the exons of the genes listed in Table 2,
- wherein each of the labeled oligonucleotides comprises a sequence specifically hybridizing to one of the microsatellite regions;
- wherein the maximal amount of the labeled oligonucleotides the kit comprises is limited to the number necessary to specifically genotype the at least 4 microsatellite regions;
- and wherein the label of the labeled oligonucleotides is a non-nucleic acid label.
A kit for determining microsatellite instability in 4 to 138 microsatellite regions of a tumor or cancer sample, the kit comprising:
- labeled oligonucleotides to genotype 4 to 138 microsatellite regions selected from those present in 5′ UTR or 3′ UTR regions from the genes listed in Table 1 and those present in the exons of the genes listed in Table 2,
- wherein each of the labeled oligonucleotides comprises a sequence specifically hybridizing to one of the microsatellite regions;
- wherein the maximal amount of the labeled oligonucleotides the kit comprises is limited to the number necessary to specifically genotype the 4 to 138 microsatellite regions;
- and wherein the label of the labeled oligonucleotides is a non-nucleic acid label.
Dependencies are inferred from the claim text.